Stereotyped B-cell receptors in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 10, 2014, Pages 2252-2261

  Agathangelidis, Andreas ^a   Vardi, Anna ^b   Baliakas, Panagiotis ^c   Stamatopoulos, Kostas ^b,c,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b G PAPANICOLAOU HOSPITAL   (Greece)

^c UPPSALA UNIVERSITY   (Sweden)

^d INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

Author keywords

B cell receptors; BcR IG; Chronic lymphocytic leukemia

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN; MICRORNA; ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE ANTIGEN RECEPTOR;

CANCER PROGNOSIS; CANCER RESEARCH; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; HUMAN; NONHUMAN; ONTOGENY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; CLONAL EVOLUTION; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; MUTATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS; CLONAL EVOLUTION; DNA METHYLATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC VARIATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOGLOBULINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICRORNAS; MUTATION; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84921863493     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.879715     Document Type: Review

References (101)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
2. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
3. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011;117:1781-1791.
4. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.
5. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
6. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-1525.
7. Stamatopoulos K, Belessi C, Hadzidimitriou A, et al. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 2005;106:3575-3583.
8. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004;200: 519-525.
9. Widhopf GF 2nd, Rassenti LZ, Toy TL, et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004;104:2499-2504.
10. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2879-2885.
11. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007;109:259-270.
12. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008;111:1524-1533.
13. Bomben R, Dal Bo M, Capello D, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol 2009;144:492-506.
14. Darzentas N, Hadzidimitriou A, Murray F, et al. A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia 2010;24:125-132.
15. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012;119:4467-4475.
16. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2- 14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101:4952-4957.
17. Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004;113:1008-1016.
18. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005;105: 1678-1685.
19. th EHA meeting, 14-17 June 2012, Amsterdam, The Netherlands.
20. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3- 21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006;107:2889-2894.
21. Hashimoto S, Wakai M, Silver J, et al. Biased usage of variable and constant-region Ig genes by IgG+, CD5+ human leukemic B cells. Ann NY Acad Sci 1992;651:477-479.
22. Athanasiadou A, Stamatopoulos K, Gaitatzi M, et al. Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins. Haematologica 2008;93:473-474.
23. Marincevic M, Cahill N, Gunnarsson R, et al. High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with "stereotyped" IGHV3-21 and IGHV4-34 B-cell receptors. Haematologica 2010;95:1519-1525.
24. Schweighofer CD, Huh YO, Luthra R, et al. The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19) (q32;q13) demonstrates remarkable stereotypy. Int J Cancer 2011;128:2759-2764.
25. Strefford JC, Sutton LA, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 2013;27:2196-2199.
26. Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood 2013;121:4902-4905.
27. Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300:455.
28. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012;44:1236-1242.
29. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50.
30. Kanduri M, Cahill N, Goransson H, et al. Differential genomewide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010;115:296-305.
31. Kanduri M, Marincevic M, Halldorsdottir AM, et al. Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics 2012;7:1435-1442.
32. Marincevic M, Mansouri M, Kanduri M, et al. Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Haematologica 2010;95:2072-2079.
33. Mansouri L, Gunnarsson R, Sutton LA, et al. Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia. Am J Hematol 2012;87:737-740.
34. Del Giudice I, Chiaretti S, Santangelo S, et al. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between BCR structure, function and patients' prognosis. Am J Hematol 2014; 89:74-82.
35. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
36. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011;12:99-110.
37. O'Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:111-122.
38. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011;11:163-175.
39. Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010;1799:694-701.
40. Valeri N, Vannini I, Fanini F, et al. Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome 2009;20:573-580.
41. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-15529.
42. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-1801.
43. Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009;113:5237-5245.
44. Rossi S, Shimizu M, Barbarotto E, et al. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010;116: 945-952.
45. Ferracin M, Zagatti B, Rizzotto L, et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer 2010;9:123.
46. Moussay E, Palissot V, Vallar L, et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 2010;9:115.
47. Pallasch CP, Patz M, Park YJ, et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 2009;114:3255-3264.
48. Frenquelli M, Muzio M, Scielzo C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010; 115:3949-3959.
49. Wang M, Tan LP, Dijkstra MK, et al. miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 2008;215:13-20.
50. Papakonstantinou N, Ntoufa S, Chartomatsidou E, et al. Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol Med 2013;19:115-123.
51. Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA- 101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695-1699.
52. Cao P, Deng Z, Wan M, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 2010;9:108.
53. Binder M, Muller F, Jackst A, et al. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 2011;117:1891-1900.
54. Broker BM, Klajman A, Youinou P, et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1988;1:469-481.
55. Sthoeger ZM, Wakai M, Tse DB, et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 1989;169:255-268.
56. Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005; 115:1636-1643.
57. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008;111:3838-3848.
58. Chu CC, Catera R, Hatzi K, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008;112:5122-5129.
59. Conti MA, Adelstein RS. Nonmuscle myosin II moves in new directions. J Cell Sci 2008;121:11-18.
60. Chu CC, Catera R, Zhang L, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010;115:3907-3915.
61. Kostareli E, Hadzidimitriou A, Stavroyianni N, et al. Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Leukemia 2009;23:919-924.
62. Kostareli E, Gounari M, Janus A, et al. Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3- 20 receptors with rheumatoid factor activity. Leukemia 2012;26:1127-1131.
63. Gounari M, Ntoufa S, Chu C, et al. Promiscuous antigen reactivity may underlie clinical aggressiveness and increased risk for Richter's syndrome in chronic lymphocytic leukemia with stereotyped IGHV4-39/IGKV1(D)-39 B cell receptors. Blood 2012;120(Suppl. 1): Abstract 561.
64. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-680.
65. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005;17:338-344.
66. Meyer-Bahlburg A, Khim S, Rawlings DJ. B cell intrinsic TLR signals amplify but are not required for humoral immunity. J Exp Med 2007;204:3095-3101.
67. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006;36:810-816.
68. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005;202:1171-1177.
69. Jahrsdorfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005;77:378-387.
70. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999-1006.
71. Spaner DE, Shi Y, White D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006;20:286-295.
72. Shi Y, White D, He L, et al. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007;67:1823-1831.
73. Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 2011;96:1644-1652.
74. Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med 2012;18:1281-1291.
75. th EHA meeting, 13-16 June 2013, Stockholm, Sweden.
76. Stamatopoulos KGP, Rosenquist R. New biological prognostic markers in CLL. Milan, Italy: Wolters Kluwer; 2010.
77. Rosenquist R, Cortese D, Bhoi S, et al. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leuk Lymphoma 2013;54:2351-2364.
78. Lanham S, Hamblin T, Oscier D, et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003;101: 1087-1093.
79. Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008;112:188-195.
80. Hivroz C, Geny B, Brouet JC, et al. Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositolspecific phospholipase C. J Immunol 1990;144:2351-2358.
81. Semichon M, Merle-Beral H, Lang V, et al. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia 1997;11:1921-1928.
82. PI3K-delta inhibitor produces long-lasting responses. Cancer Discov 2013;3:OF11.
83. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
84. Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 2009;15:4415-4422.
85. Maura F, Visco C, Falisi E, et al. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 2013;88:32-36.
86. Visco C, Maura F, Tuana G, et al. Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. Clin Cancer Res 2012;18:1870-1878.
87. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262-2264.
88. Cunningham AF, Gaspal F, Serre K, et al. Salmonella induces a switched antibody response without germinal centers that impedes the extracellular spread of infection. J Immunol 2007;178: 6200-6207.
89. Rothaeusler K, Baumgarth N. B-cell fate decisions following influenza virus infection. Eur J Immunol 2010;40:366-377.
90. Chappell CP, Draves KE, Giltiay NV, et al. Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses. J Exp Med 2012;209:1825-1840.
91. Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 2005;26:347-362.
92. Montecino-Rodriguez E, Dorshkind K. B-1 B cell development in the fetus and adult. Immunity 2012;36:13-21.
93. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20 + CD27 + CD43 + CD70. J Exp Med 2011;208:67-80.
94. Kaji T, Ishige A, Hikida M, et al. Distinct cellular pathways select germline-encoded and somatically mutated antibodies into immunological memory. J Exp Med 2012;209:2079-2097.
95. Taylor JJ, Pape KA, Jenkins MK. A germinal center-independent pathway generates unswitched memory B cells early in the primary response. J Exp Med 2012;209:597-606.
96. Potter KN, Mockridge CI, Neville L, et al. Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res 2006;12:1672-1679.
97. Vardi A, Agathangelidis A, Sutton LA, et al. IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications. Clin Cancer Res 2014;20:323-330.
98. Bhat NM, Bieber MM, Spellerberg MB, et al. Recognition of auto- and exoantigens by V4-34 gene encoded antibodies. Scand J Immunol 2000;51:134-140.
99. Richardson C, Chida AS, Adlowitz D, et al. Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus. J Immunol 2013;191:4926-4939.
100. Hadzidimitriou A, Darzentas N, Murray F, et al. Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. Blood 2009;113: 403-411.
101. Catera R, Magli A, Kolitz J, et al. Somatic hypermutation in stereotyped subset 4 BcRs/mAbs of CLL patients, expressing IGHV4-34 gene, edits anti-DNA reactivity. Blood 2011;118(Suppl. 1): Abstract 2444.